Clinical trials: Renin Hypertension
Kidney, Polycystic
HALT Progression of Polycystic Kidney Disease Study B
The efficacy of interruption of the renin-angiotensin-aldosterone system (RAAS) on the progression of cystic disease and on the decline in renal function in autosomal dominant kidney disease (ADPKD) will be assessed in two…
- Trial name
- HALT PKD B (NCT01885559)
- Testing
- Lisinopril, Telmisartan
- Where
- 7 sites in United States
- Volunteers
- 486 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Obesity, Vitamin D Deficiency
Vitamin D Supplementation Reduces Renin-Angiotensin System Activity in Obesity
Hypothesis: Vitamin D supplementation lower renin-angiotensin system activity in obesity. Specific Aim: To investigate whether Vitamin D supplementation in obesity improves the vascular sensitivity to angiotensin II.
- Conditions
- Obesity, Vitamin D Deficiency, Hypertension
- Trial name
- NCT01068418
- Testing
- Vitamin D (cholecalciferol)
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Brigham and Women's Hospital
Hypertension
Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension
This study evaluated the efficacy (blood pressure lowering effect) and safety of aliskiren/amlodipine/hydrochlorothiazide in patients with moderate to severe hypertension.
- Trial name
- NCT00765674
- Testing
- Aliskiren, Amlodipine, Hydrochlorothiazide (HCTZ)
- Where
- 12 sites in United States, Australia and 10 more
- Volunteers
- 1,191 people
- Sponsor
- Novartis
Hypertension, Abdominal Obesity
Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension
Part 1 determined: aliskiren, amlodipine and angiotensin II concentrations in interstitial fluid of fat and skeletal muscle; aliskiren and angiotensin II concentrations, and renin activity and concentration in fat and skeletal…
- Trial name
- NCT00498433
- Testing
- Aliskiren, Amlodipine
- Where
- 2 sites in Germany
- Volunteers
- 46 people
- Sponsor
- Novartis
Arterial Hypertension, Hemodialysis
Mechanisms and Phenotypes of Hypertension in Patients in Chronic Hemodialysis
The goal of this study is to evaluate interdialytic blood pressure changes of the patients in chronic hemodialysis. The main question to be answered is: What is the relative importance of weight gain, the renin angiotensin…
- Trial name
- NCT06764277
- Testing
- There will be no intervention
- Where
- Mexico
- Volunteers
- 32 people
- Sponsor
- Bernardo Rodríguez Iturbe
Hypertension
Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS)
In this study the investigators will recruit hypertensive subjects with higher than average uric acid levels to test the effect of lowering uric acid with febuxostat on several measures as listed below.
- Trial name
- NCT01328769
- Testing
- Febuxostat
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Paul N. Hopkins
Diabetes Mellitus, Non-Insulin-Dependent, Hypertensive Disease
To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study
The investigators are conducting this research to study the effect of Liraglutide on blood pressure. Several studies have shown increased cardiovascular complications and deaths in diabetics with hypertension.
- Trial name
- NCT02299388
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Tulane University School of Medicine
Hyperkalemia
Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)
The purpose of this study is to assess the effects of patiromer compared with placebo on serum K+ in HF patients.
- Trial name
- DIAMOND (NCT03888066)
- Testing
- Patiromer
- Where
- 415 sites in United States, Argentina and 19 more
- Volunteers
- 1,195 people
- Sponsor
- Vifor Pharma, Inc.
Type 2 Diabetes Mellitus, Hypertension
Shiga Microalbuminuria Reduction Trial-2
The purpose of this study is to compare the effects of a direct renin inhibitor (DRI), aliskiren, on the urinary albumin excretion in hypertensive patients with type 2 diabetes under strict blood pressure control with angiotensin…
- Trial name
- NCT01461499
- Testing
- Aliskiren, any angiotensin receptor blockers
- Where
- Japan
- Volunteers
- 237 people
- Sponsor
- Shiga University
Hypertension
A Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of Age
This first open-label study in a pediatric population was designed to evaluate aliskiren safety and pharmacokinetics after single and multiple dosing in 6-17 year old children with hypertension.
- Trial name
- NCT00834041
- Testing
- Aliskiren 3.125 mini-tablets
- Where
- 5 sites in United States, Belgium and 3 more
- Volunteers
- 39 people
- Sponsor
- Novartis
Hypertension With Metabolic Syndrome
Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome
This proof of concept study is designed to evaluate the efficacy and safety of the combination therapy of aliskiren and ramipril as add-on to amlodipine in the treatment of patients with essential hypertension and metabolic…
- Trial name
- ALTO (NCT00542269)
- Testing
- Amlodipine, Aliskiren, Ramipril
- Where
- United Kingdom
- Volunteers
- 178 people
- Sponsor
- Novartis
Kidney, Polycystic
HALT Progression of Polycystic Kidney Disease Study A
The efficacy of interruption of the renin-angiotensin-aldosterone system (RAAS) on the progression of cystic disease and on the decline in renal function in autosomal dominant kidney disease (ADPKD) will be assessed in two…
- Trial name
- HALT PKD A (NCT00283686)
- Testing
- Lisinopril, Telmisartan, Standard Blood Pressure Control
- Where
- 7 sites in United States
- Volunteers
- 558 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Arterial Hypertension
Registry for Ambulant Therapy With RAS-Inhibitors in Hypertension-patients in Germany
In Germany nearly half of the population present elevated values of blood pressure, with - as a result of lifestyle factors and a growing average age - further increasing numbers.
- Trial name
- 3A (NCT01454583)
- Testing
- Aliskiren, ACE-I/ARB, No RAS-inhibition
- Volunteers
- 15,337 people
- Sponsor
- Stiftung Institut fuer Herzinfarktforschung
Systemic Arterial Hypertension, Hypertension Resistant to Conventional Therapy
Renin-angiotensin-aldosterone System Polymorphisms in Resistant Hypertension and Adverse Cardiovascular Events
Renin-angiotensin-aldosterone system (RAAS) polymorphisms influence 24h arterial pressure fluctuation. Resistant systemic arterial hypertension (RSAH) has an increased risk of end organ damage and unfavourable prognosis, whereas…
- Conditions
- Systemic Arterial Hypertension, Hypertension Resistant to Conventional Therapy, Myocardial Infarction, Stroke
- Trial name
- GENHART (NCT01173029)
- Testing
- Anti-hypertensive drug treatment
- Where
- Brazil
- Volunteers
- 92 people
- Sponsor
- Universidade Gama Filho
Hypertension
Combined Renin Inhibition/Beta-blockade
Antihypertensive drug treatment is effective in only about 50% of patients. One mechanism responsible for treatment failure is a drug related stimulation of the renin-angiotension-aldosterone-system (RAAS).
- Trial name
- NCT00627861
- Testing
- Aliskiren, Extended-release metoprolol
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- The Rogosin Institute
Vitamin D Deficiency, Hypertension
Vitamin D Deficiency in Patients With Hypertension
This study will evaluate the effects of Vitamin D replacement and the effects of an approved medication for hypertension, aliskiren (Tekturna), in patients with high blood pressure who have low levels of vitamin D in their blood.
- Trial name
- NCT00974922
- Testing
- Aliskiren, Cholecalciferol
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- UConn Health
Hypertension, Plasma Renin Activity
A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension
The purpose of this study is to investigate the effect of plasma renin activity-guided therapy for determining hypertension treatment.
- Trial name
- NCT01658657
- Testing
- Hydrochlorothiazide, Lisinopril, Amlodipine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of North Carolina, Chapel Hill
High Blood Pressure
The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function
Aliskiren (also called TekturnaTM) is a new drug for high blood pressure. Aliskiren works by blocking the actions of a substance called renin. Renin is a natural substance in the body that raises blood pressure.
- Trial name
- NCT03115853
- Testing
- Aliskiren 150 mg, HCTZ, Aliskiren 300 mg
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Vanderbilt University Medical Center
Diabetes, Pre-hypertension
Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects
The study will evaluate the effects of the direct renin inhibitor, aliskiren, on flow-mediated dilation of the brachial artery and on central aortic pressure in diabetic patients with pre-hypertension or Stage 1 hypertension.
- Conditions
- Diabetes, Pre-hypertension, Hypertension
- Trial name
- NCT01349114
- Testing
- aliskiren 300 mg once daily
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Alabama at Birmingham
Obesity, Prehypertension
Vascular Dysfunction in Human Obesity Hypertension
The purpose of the study is to test the effects of blocking sympathetic nerve activity with a drug called clonidine on blood vessel function and muscle nerve activity in adults who are obese and have high blood pressure.
- Conditions
- Obesity, Prehypertension, Hypertension
- Trial name
- VANISH (NCT01983462)
- Testing
- Clonidine, Hydrochlorothiazide
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Gary L. Pierce